Mark A. Agius
University of California, Davis
60 Papers
615 Citations
Mark A. Agius is an academic researcher from University of California, Davis. The author has contributed to research in topics: Myasthenia gravis & Medicine. The author has an hindex of 24, co-authored 59 publications. Previous affiliations of Mark A. Agius include United States Department of Veterans Affairs & St. Joseph's Hospital and Medical Center.
Chat about Author
Papers
Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.
Peter A. Calabresi,Ernst Wilhelm Radue,Douglas S. Goodin,Douglas Jeffery,Kottil Rammohan,Anthony T. Reder,Timothy Vollmer,Mark A. Agius,Mark A. Agius,Ludwig Kappos,Tracy Stites,Bingbing Li,Linda Cappiello,Philipp von Rosenstiel,Fred D. Lublin +14 more
TL;DR: The findings substantiate the beneficial profile of fingolimod as a disease-modifying agent in the management of patients with relapsing-remitting multiple sclerosis and strengthen evidence for its beneficial effects on relapse rates in patients with relapse rates.
798
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky,Ponnada A. Narayana,Paul O'Connor,P. K. Coyle,Corey C. Ford,Kenneth P. Johnson,Kenneth P. Johnson,Aaron Miller,Aaron Miller,Lillian Pardo,Shaul Kadosh,David Ladkani,Lorne F. Kastrukoff,Pierre Duquette,Mark S. Freedman,Marc Debouverie,Catherine Lubetski,Gilles Edan,E Roullet,Christian Confavreux,Alan J. Thompson,L D Blumhardt,L D Blumhardt,Stanley Hawkins,Thomas F. Scott,Daniel Wynn,Joanna Cooper,Stephen Thurston,Stanton B. Elias,Clyde E. Markowitz,David Mattson,John H. Noseworthy,Elizabeth A. Shuster,Jonathan L. Carter,Fred D. Lublin,WH Stuart,Michael D. Kaufman,Gary Birnbaum,Kottil Rammohan,Ruth H. Whitham,Cornelia Mihai,Steven J. Greenberg,Craig M. Smith,Mark A. Agius,Stan Van Den Noort,Lawrence W. Myers,James G. Nelson,Douglas S. Goodin,Barry G. W. Arnason,Khurram Bashir,Sharon G. Lynch,Patricia K. Coyle,Stephen Kamin,William A. Sheremata,Galen Mitchell,Andrew D. Goodman,Norman J Kachuck,Peter B. Dunne,J. William Lindsey,Elliot M. Frohman,James D. Bowen,Benjamin Rix Brooks,John W. Rose,Harold L. Moses,Douglas Jeffrey,Anne H. Cross,Robert P. Lisak,Timothy Vollmer,Jack P. Antel,Gary Cutter,Luanne M. Metz,Henry F. McFarland,Steven Reingold,Fred D. Lublin,Irina Vainrub,Lucie Lambert,Fengwei Zhong,Jeff Rasmituth,Saria Momin,Rivka Kreitman,Galia Shifroni,Irit Pinchasi,Yafit Stark +82 more
TL;DR: To determine whether glatiramer acetate slows accumulation of disability in primary progressive multiple sclerosis, a new drug is developed that acts as a ‘spatially aggregating agent’ to reduce the risk of disease progression.
447
Treatment of autoimmune myasthenia gravis
David P. Richman,Mark A. Agius +1 more
TL;DR: Immune-directed treatment of patients with MG is aimed at inducing an immunologic remission and then maintaining that remission, usually accomplished by slow tapering of the corticosteroids along with the use of “steroid-sparing” agents, which include azathioprine, thymectomy, and possibly mycophenolate.
199
Morvan's fibrillary chorea: a paraneoplastic manifestation of thymoma.
TL;DR: The association of thymoma with other autoimmune disorders and autoantibodies, and prolonged and sustained remission with chronic immunosuppression, place Morvan’s fibrillary chorea on the range of neurological diseases arising as a paraneoplastic complication of cortical thymomas.
165
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Bruce A.C. Cree,Gary Cutter,Jerry S. Wolinsky,M. S. Freedman,Giancarlo Comi,Gavin Giovannoni,Hans-Peter Hartung,Douglas L. Arnold,Jens Kuhle,Valerie J Block,Frederick E. Munschauer,Frédéric Sedel,Fred D. Lublin,Stephen C. Reingold,Pierre Duquette,Tobias Derfuss,Franz Fazekas,Maria Pia Sormani,Robert P. Lisak,Jennifer Graves,Stephen Krieger,Rana K. Zabad,Scott D. Newsome,Joshua Barton,Richard MacDonell,Mark Marriott,Nina De Klippel,Guy Laureys,Barbara Willekens,Virginia Devonshire,Mark S. Freedman,J. Marc Girard,Paul S. Giacomini,Roger McKelvey,Daniel Selchen,Galina Vorobeychik,Ludivine Witkowski,Radek Ampapa,Jana Lizrova Preiningerova,Eva Meluzinova,R. Talab,Marta Vachova,Orhan Aktas,Mathias Buttmann,Elias Hamp Birte,Tania Kuempfel,Paul Friedemann,Daniela Rau,Gerd Reifschneider,Piotr Sokolowski,Hayrettin Tumani,Maria Satori,Carlo Pozzilli,Agata Klosek,Jozef Koscielniak,Fryze Waldemar,Malgorzata Zajda,Rafael Arroyo Gonzalez,Guillermo Izquierdo Ayuso,Victoria Fernandez Sanchez,Celia Oreja Guevara,Jose Enrique Martinez Rodriguez,Xavier Montalban,Lluís Ramió-Torrentà,Lou Brundin,Jan Lycke,Murat Terzi,Joe Guadagno,Don J. Mahad,Adrian Pace,Klaus Schmierer,Ahmed T. Toosy,Stewart Webb,Mark A. Agius,Lilyana Amezcua,Michelle L Apperson,Bridget Bagert,Daniel Bandari,Evanthia Bernitsas,Jonathan Calkwood,Jonathan Carter,Bruce A. Cohen,Devon S. Conway,Joanna Cooper,John R. Corboy,Patricia K. Coyle,Bruce C.A. Cree,Mitchel Freedman,Corey C. Ford,Edward Fox,Myla D. Goldman,Benjamin Greenberg,Mariko Kita,Thomas Leist,Sharon G. Lynch,Aaron E. Miller,Harold L. Moses,Robert T. Naismith,Mary Ann Picone,Bhatia Perminder,Alexander Rae-Grant,Kottil Rammohan,Anthony T. Reder,Claire S Riley,Derrick Robertson,Vernon Rowe,Shiv Saidha,Lawrence Samkoff,Christopher Severson,Kyle Smoot,Sharon Stoll,Randall Trudell,Bianca Weinstock-Guttman,Sanjay Yathiraj +113 more
TL;DR: This study showed that MD 1003 did not significantly improve disability or walking speed in patients with progressive multiple sclerosis and thus, in addition to the potential of MD1003 for deleterious health consequences from interference of laboratory tests, MD1002 cannot be recommended for treatment of progressive multipleclerosis.